English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/201568
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Advances in the Development of Non-steroidal Mineralocorticoid-receptor Antagonists

AuthorsPérez-Gordillo, Felipe L.; Pérez de Vega, M. Jesús; Gerona-Navarro, G.; Rodríguez, Y.; Alvarez de la Rosa, Diego; González-Muñiz, Rosario CSIC ORCID; Martín-Martínez, Mercedes CSIC ORCID
KeywordsMineralocorticoid receptor
MR antagonist
Structure-activity relationship
Clinical trials
Issue Date2020
PublisherInTechOpen
CitationAldosterone-Mineralocorticoid Receptor (Cell Biology to Translational Medicine): 257-275 (2020)
AbstractThe mineralocorticoid receptor (MR) belongs to the nuclear receptor superfamily and regulates body fluid and electrolyte balance. In the last years, much effort has been put into the development of non-steroidal MR antagonists that overcome the side effects of the marketed steroid drugs, and can be used for the treatment of hypertension and heart failure, among others. Initially, MR was identified in epithelial cells, however it also plays important roles in non-epithelial tissues. In this sense, it is of interest to discover ligands that might induce different MR conformational changes, leading to specific coregulator interactions, which could confer tissue-specific effects. Different series of non-steroidal ligands with diverse central scaffolds has been described, which shows antihypertensive and cardiorenal protective effects. This review covers a description of different non-steroidal MR antagonist families, with special focus on compounds under clinical development. The analysis of the three-dimensional (3D) structures of non-steroidal MR antagonists in complex with the MR ligand-binding domain (LBD), recently reported, highlights the interactions crucial for binding. The structure-activity relationships of known ligands, together with the insights provided by the 3D structures of ligand - LBD MR complexes, could help in the development of non-steroidal MR antagonists with improved properties.
Publisher version (URL)http://dx.doi.org/10.5772/intechopen.88417
URIhttp://hdl.handle.net/10261/201568
Appears in Collections:(IQM) Libros y partes de libros
Files in This Item:
File Description SizeFormat 
778591.pdf1,8 MBUnknownView/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.